AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01759446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vycavert taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study NCT01759446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A plus i taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study NCT01759446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A plus p taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study NCT02817009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
Study NCT02817009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Session
Description: Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
Study NCT02817009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Session
Description: 45 minutes physical activity session to promote healthy behaviors
Study NCT03763877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Oral capsule
Study NCT03763877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Oral capsule
Study NCT00528034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
Study NCT02915822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Chevron/Akin osteotomy
Description: Minimally invasive technique for hallux valgus correction
Study NCT02915822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Scarf/Akin osteotomy
Description: Open technique for Hallux Valgus correction
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narlaprevir
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg, film-coated tablets, taken as 300 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg, film-coated tablets, taken as 300 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400 mg, film-coated tablets, taken as 400 mg per os daily
Study NCT03537404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg, film-coated tablets, taken as 400 mg per os daily
Study NCT01523093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8mg
Study NCT01523093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8mg
Study NCT06416124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric assessment
Description: A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
Study NCT00183482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Group Cognitive Behavioral
Description: Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
Study NCT00183482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Families are mailed written materials that describe depression and stress in families with a depressed parent.
Study NCT04613037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation in adults with Atopic Dermatitis
Study NCT04259996 — intervention group
Intervention type: PROCEDURE
Intervention: PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT
Description: The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
Study NCT03443570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
Study NCT03443570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
Study NCT03443570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
Study NCT03847896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)
Description: Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
Study NCT03847896 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)
Description: Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
Study NCT03847896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide metered dose inhaler / BD MDI 160 µg
Description: Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
Study NCT03847896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered dose inhaler / AS MDI 180 μg
Description: Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
Study NCT03847896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo metered-dose inhaler / Placebo MDI
Description: Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
Study NCT03970317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broad Band Light
Description: Broad Band Light Device
Study NCT03473509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD Registry
Description: Health Service intervention
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 Initial fit for purpose tablets
Description: Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 over granulated tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 intended commercial tablets
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-GSK1322322 stable isotope powder
Description: White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 for injection
Description: White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
Study NCT01818011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
Study NCT03960996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dacryocystorinostomy
Description: Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
Study NCT04522544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300 mg Tremelimumab C1D1
Study NCT04522544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
Study NCT04522544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y-90 SIRT
Description: Locoregional therapy will be performed as a standard-of-care procedure
Study NCT04522544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: Locoregional therapy will be performed as a standard-of-care procedure
Study NCT02695563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Study NCT01315639 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biomarkers, MRI and CSF
Description: MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
Study NCT00487656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 6mg/ml ampule solution for injection @ .01mg/kg
Study NCT00487656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 mg/ml ampule solution for injection at .01mg/kg
Study NCT01111799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
Study NCT01111799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural cycle + IUI + endometrial biopsy
Description: two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
Study NCT03578783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Study NCT03578783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSD502
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Study NCT00045617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 11D10 anti-idiotype vaccine
Study NCT00045617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody GD2 anti-idiotype vaccine
Study NCT00045617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00045617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00045617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02335788 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The EMBA Peripheral Embolization Device
Description: arterial and venous embolization in the peripheral vasculature
Study NCT01039519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
Study NCT01229267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
Study NCT01229267 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Vaccine stabilizer for V212 with no virus antigen
Study NCT03329638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution low dose
Description: Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study NCT03329638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution medium dose
Description: Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study NCT03329638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-127 Ophthalmic Solution high dose
Description: High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study NCT03329638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution dosed once daily for 12 months
Study NCT03678220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapAR
Description: LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
Study NCT01718405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive function after exercise test
Description: The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
Study NCT01718405 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample analysis
Description: In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
Study NCT02013271 — intervention group
Intervention type: DEVICE
Intervention: Lutonix Paclitaxel Drug Coated Balloon (DCB)
Description: Patients exposed to the DCB as part of their routine care.
Study NCT00184301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment
Description: inpatient treatment during 1 year
Study NCT00184301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: outpatient treatment
Description: intensive outpatient treatment consisting of two-weekly group sessions during 1 year
Study NCT04441918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS016 (anti-SARS-CoV-2 monoclonal antibody)
Description: JS016 (anti-SARS-CoV-2 monoclonal antibody)
Study NCT01956929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
Study NCT01956929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
Study NCT03543917 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perfusion with New Combination Medication
Description: Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
Study NCT03652285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal stent implantation
Description: An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement.
Study NCT03652285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent removal
Description: Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
Study NCT00004554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone (Revia)
Description: 100mg/day
Study NCT00004554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline (Zoloft)
Description: 200mg/day
Study NCT00004554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04259619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)\^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
Study NCT04259619 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Therapy
Description: The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
Study NCT02025413 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Study NCT00254384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00254384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT00254384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT00254384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00254384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04294680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: see opiate sparing description
Study NCT00985361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 international units daily
Description: Vitamin D3 2000 international unit tablets once daily for 3 months
Study NCT00985361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500mg daily
Description: Vitamin C 500mg tablets once daily for 3 months
Study NCT03669497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo fractionated whole breast radiotherapy
Description: Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
Study NCT01926262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Strength Training
Description: Specific Strength Training for the Neck and Shoulder Muscles